Results

Total Results: over 10,000 records

Showing results for "drugs".

  1. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/43942/psn-pdf
    March 11, 2015 - FDA requires label warnings to prohibit sharing of multi- dose diabetes pen devices among patients. March 11, 2015 FDA Safety Communication. Silver Spring, MD: US Food and Drug Administration; February 25, 2015. https://psnet.ahrq.gov/issue/fda-requires-label-warnings-prohibit-sharing-multi-dose-diabetes-pen-device…
  2. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/44771/psn-pdf
    January 06, 2016 - Could it be done safely? Pharmacists views on safety and clinical outcomes from the introduction of an advanced role for technicians. January 6, 2016 Napier P, Norris P, Braund R. Could it be done safely? Pharmacists views on safety and clinical outcomes from the introduction of an advanced role for technicians. R…
  3. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/43210/psn-pdf
    May 28, 2014 - Improving cancer patient care with combined medication error reviews and morbidity and mortality conferences. May 28, 2014 Ranchon F, You B, Salles G, et al. Improving Cancer Patient Care with Combined Medication Error Reviews and Morbidity and Mortality Conferences. Chemotherapy (Los Angel). 2014;59(5). doi:10.11…
  4. www.ahrq.gov/patient-safety/reports/national-action-plans.html
    February 01, 2018 - National Action Plans The work of AHRQ and other Federal agencies is guided by work groups, committees, investigators and expert advisors who contribute to reports on specific topics that impact health care. National Action Plans National Action Plans are developed with expert input to provide a framework f…
  5. www.ahrq.gov/sites/default/files/wysiwyg/data/SyH-DR-Pharmacy-Level-claims-2024.pdf
    January 01, 2024 - SyH-DR Data Dictionary: Pharmacy-Level Variables SyH-DR Data Dictionary: Pharmacy-Level Variables Variable Label Variable Name Medicare File Medicaid File Commercial File Variable Type Variable Length Synthesized, Masked, Suppressed Note / Rule** Claim Number CLM_CNTL_NUM X NUM 8 Masked…
  6. www.ahrq.gov/prevention/guidelines/tobacco/clinicians/presentations/2008update-full/slide127.html
    October 01, 2014 - 127. Treatment Recommendations: Medications (Continued) Treating Tobacco Use and Dependence: 2008 Update Text version of slide presentation. Clinical guidelines for prescribing medication for treating tobacco use and dependence (continued) When should second-line agents be used for treating tobacc…
  7. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/844987/psn-pdf
    February 22, 2023 - Examining medication ordering errors using AHRQ Network of Patient Safety Databases. February 22, 2023 Grauer A, Rosen A, Applebaum JR, et al. Examining medication ordering errors using AHRQ network of patient safety databases. J Am Med Inform Assoc. 2023;30(5):838-845. doi:10.1093/jamia/ocad007. https://psnet.ahr…
  8. www.uspreventiveservicestaskforce.org/uspstf/integrating-evidence-based-clinical-and-community-strategies-to-improve-health---table-1
    November 01, 2013 - Integrating Evidence-Based Clinical and Community Strategies to Improve Health - Table 1 Share to Facebook Share to X Share to WhatsApp Share to Email Print The Leading and Actual Causes of Death, United States, 2000 Leading cause of …
  9. www.ahrq.gov/sites/default/files/wysiwyg/data/infographics/qdr-infographic-opioids.pdf
    January 01, 2013 - Dramatic Rise in Opioid-Related Deaths, Especially Among Blacks Dramatic Rise in Opioid-Related Deaths, Especially Among Blacks Non-Hispanic Blacks 18-fold increase in mortality Non-Hispanic Whites 9-fold increase in mortality Hispanics 12-fold increase in mortality 0.5 to 9 deaths per 100,000 populat…
  10. effectivehealthcare.ahrq.gov/sites/default/files/pdf/rapid-reviews-end-user_white-paper.pdf
    April 01, 2016 - the increasing interest in rapid reviews and their methodologies, including the Canadian Agency for Drugs … The Evidence Inventory was produced by the Canadian Agency for Drugs and Technologies in Health, 11 … literature and pertinent research issues; Horizon Scanning aims to identify new, or new uses of existing, drugs … Canadian Agency for Drugs in Technologies in Health.
  11. effectivehealthcare.ahrq.gov/sites/default/files/pdf/coronary-artery-disease-testing_research-protocol.pdf
    January 15, 2015 - renal failure, allergy, nephrogenic systemic fibrosis, contrast-related harms, adverse reactions to drugs … Technologies that are no longer available or no longer widely used (e.g., MUGA, planar nuclear imaging) • Drugs … without myocardial echo contrast) A person’s heart is stressed either through exercise or the use of drugs … Pharmacologic stress magnetic resonance imaging (MRI) Drugs are used to stress the heart and then an
  12. effectivehealthcare.ahrq.gov/sites/default/files/related_files/registries-guide-2nd-edition_disposition-comments.pdf
    March 03, 2010 - thereby allowing legitimate comparisons, to the extent possible, across types and generations of drugs … Source: www.effectivehealthcare.ahrq.gov Published Online: March 3, 2010 Page 12, Orphan Drugs … interpretable long‐term safety data as they may allow objective comparisons across generations of drugs
  13. hcup-us.ahrq.gov/reports/SOI.jsp
    June 01, 2016 - A Severity-of-Illness Classificiation for Mental and Substance-Use Disorders for Use With Hospital Administrative Data An official website of the Department of Health & Human Services Search All AHRQ We…
  14. hcup-us.ahrq.gov/reports/ED_MHSA_SOIpaper.pdf
    June 10, 2011 - A sample article title MAINTAIN AND EXPAND THE HEALTHCARE COST AND UTILIZATION PROJECT (HCUP) Contract No. HHSA-290-2006-00009-C A SEVERITY-OF-ILLNESS CLASSIFICATION FOR MENTAL AND SUBSTANCE-USE DISORDERS FOR USE WITH HOSPITAL ADMINISTRATIVE DATA June 10, 2011 …
  15. effectivehealthcare.ahrq.gov/sites/default/files/pdf/fibromyalgia_research-protocol.pdf
    April 03, 2014 - The extent to which adverse effects from treatments, especially pharmaceuticals are more common, more … Antiepileptics (such as pregabalin or gabapentin) o Non-opioid analgesics o Nonsteroidal anti-inflammatory drugs … comorbidities, other chronic pain conditions or longer duration of symptoms Adverse effects of drugs … We will also review Scientific Information Packets sent by manufacturers for relevant pharmaceuticals
  16. digital.ahrq.gov/sites/default/files/docs/publication/p20hs014908-bergner-final-report-2005.pdf
    January 01, 2005 - El Dorado County Safety Net Technology Project Grant Final Report Grant ID: 1 P20 HS014908-01 El Dorado County Safety Net Technology Project Inclusive dates: 09/30/04 - 09/29/05 Principal Investigator: Dr. Greg Bergner Team members: Jon Lehrman Sandra Dunn Chris Weston Mike Weiher Pat …
  17. hcup-us.ahrq.gov/db/nation/nis/NIS_Sources_and_Restrictions_2001.pdf
    January 01, 2001 - Sources of NIS Data and State-Specific Restrictions 2001 AZ Arizona Department of Health Services No restrictions CA Office of Statewide Health Planning & Development No restrictions CO Colorado Health & Hospital Association No restrictions CT CHIME, Inc. …
  18. www.ahrq.gov/research/findings/making-healthcare-safer/mhs3/exe-summary.html
    March 01, 2020 - Making Healthcare Safer III: Executive Summary ES. 1 Background/Introduction The Making Health Care Safer reports from the Agency for Healthcare Research and Quality (AHRQ) have had an important role in reducing harm and improving the safety and quality of care for patients. The reports—providing an analysis …
  19. www.uspreventiveservicestaskforce.org/home/getfilebytoken/eSLqaKpvzhYRbQVeumNgSQ
    January 19, 2021 - None of the drugs were associated with serious adverse events. … Evidence is still needed to compare different forms, doses, and durations of drugs; to compare drugs … more than the use of a single NRT product (RR, 1.25 [95% CI, 1.15-1.36]) Direct comparisons between drugs
  20. digital.ahrq.gov/sites/default/files/FINAL%20OO%20PC%20CDS%20SDM%20Report.pdf
    September 01, 2023 - understand the risk of drug interactions between blood thinners and nonsteroidal anti-inflammatory drugs … Shared Decision-making Tool for Drug Interactions Between Warfarin and Nonsteroidal Anti-inflammatory Drugs